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OPENin a COVID-19 patientTo the editor The first available reports indicate that renal
involvement is relatively frequent in patients with novel
coronavirus disease 2019 (COVID-19) due to the emerging
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2). Up to 43% of patients present with proteinuria (including
10% with heavy proteinuria), 11% with hematuria, and 3.5%
to 5% with acute kidney injury.1,2 Both proteinuria and acute
kidney injury are associated with increased mortality.1 How-
ever, the exact mechanisms underlying renal injury in patients
with COVID-19 are unclear as renal pathology data are lacking.
We report on a 63-year-old black male patient who
developed acute kidney injury in the setting of COVID-19. He
had a history of hypertension treated with atenolol, nifedi-
pine, and olmesartan. He initially presented with intense fa-
tigue, high-grade fever (39.7 C), and respiratory distress
(respiratory rate, 36 breaths/min; arterial blood O2 saturation,
86%) requiring O2 supplementation (4 l/min). On admission,
his serum creatinine was 1.2 mg/dl. He was diagnosed with
COVID-19 based on a positive reverse transcriptase–
polymerase chain reaction test for SARS-CoV-2 in a naso-
pharyngeal swab sample.
Shortly after his admission, he developed oliguria and
rapidly progressive acute kidney injury (Kidney Disease:
Improving Global Outcomes stage 3) with a serum creati-
nine of 4.4 mg/dl at day 4 (Figure 1a). Laboratory tests
showed an increase in the C-reactive protein level, lym-
phopenia, increased D-dimers serum level, hypo-
albuminemia, massive proteinuria (5 g/l consisting of 50%
of albumin), and reduced sodium urinary excretion (so-
dium excretion fraction: 0.4%). The patient had no epi-
sodes of hypotension and remained hypertensive for most
of his hospital stay. His respiratory condition gradually
improved and the O2 supplementation was decreased (0.5 l/
min at day 8). Serum levels of a range of cytokines,
including interleukin-6, were normal. However, the further
increase of C-reactive protein serum levels was associated
with systemic complement activation (soluble C5b-9, Bb
fragment) and worsening of acute kidney injury with a
serum creatinine peaking at 8.4 mg/dl at day 8 (Figure 1a).
The patient did not receive SARS-CoV-2–specific experi-
mental treatment (protease inhibitors, remdesivir, and
hydroxychloroquine) or any nephrotoxic drug.
A kidney biopsy was performed at day 8. Light microscopy
examination disclosed 2 main features: severe collapsing focal
segmental glomerulosclerosis (FSGS) (Figure 1b and c) and
acute tubular necrosis (Figure 1d) without any significant
interstitial inflammation. The immunofluorescence study
revealed no significant immune deposits (including anti-C5b-
9 staining). A reverse transcriptase–polymerase chain reaction
for SARS-CoV-2 in RNA extracted from a frozen biopsy tissueKidney International (2020) -, -–-sample was negative (reverse transcriptase–polymerase chain
reaction was similarly negative in blood) (Figure 1a). Electron
microscopy study (Figure 1e and f) disclosed, in the podocyte
cytoplasm, vacuoles containing numerous spherical particles
that may correspond to viral inclusion bodies reported with
SARS-CoV-2.3
Further work-up showed that the patient was homozygous
for the at-risk apolipoprotein A (APOL1) G1 variant (A342G
and I348M). No specific treatment was implemented. The
patient maintained a urinary output and did not require
dialysis. Renal function subsequently improved and protein-
uria decreased (Figure 1a). The patient was discharged on day
17 with a serum creatinine of 5.5 mg/dl and persistent pro-
teinuria (1.8 g/l).
To the best of our knowledge, this is the first description of
the pathological features of renal injury in the setting of
COVID-19 outside autopsies series. The most striking finding
in our patient was the collapsing FSGS. This finding suggests
that FSGS could account for the heavy proteinuria reported in
a significant proportion of patients with COVID-19.1 The
collapsing FSGS is a known complication of other viral in-
fections, in particular, HIV,4 as well as cytomegalovirus5 and
parvovirus B19.6 For HIV a direct toxic viral effect on
podocytes has been documented.7 The receptor for SARS-
CoV-2, membrane-bound angiotensin-converting enzyme 2,
is expressed on podocytes.8,9 However, polymerase chain re-
action for SARS-CoV-2 was negative in kidney biopsy sam-
ples, but the technique has a notoriously low rate of detection
in nonrespiratory samples (including blood and urine),10 and
the quality of the extracted RNA material was poor. Besides,
electron microscopy findings in our patient do not provide
definite proof of the presence of SARS-CoV-2 in podocytes,
and one cannot exclude that the detected vesicles in podocytes
may correspond to nonviral particles. Collapsing FSGS, with
or without acute tubular necrosis, can also complicate the
course of hemophagocytic syndrome,11 a disorder character-
ized by an increased release of a wide range of cytokines. In
our patient, normal levels of cytokines, in particular
interleukin-6, while inflammation markers were still
increased, plead against this hypothesis. However, a potential
virus-driven intrarenal cytokines release cannot be excluded.
Besides, our patient is of African origin and is homo-
zygous for the APOL1 at-risk G1 variant. This variant may
have contributed to the pathogenesis of collapsing FSGS,
because APOL1 is a recognized risk factor for the devel-
opment collapsing FSGS in HIV and non-HIV patients.4
In our patient, acute tubular necrosis developed in the
absence of hemodynamic compromise or severe pulmonary
involvement. This suggests that tubular injury in COVID-19
patients, unlike that seen in coronavirus-associated SARS,12
is not predominantly ischemic. The possible underlying
mechanisms are a direct viral toxicity on tubular cells that also
harbor angiotensin-converting enzyme 2 or a cytokine-
mediated tubular damage. In addition, the initial heavy1
Figure 1 | A 63-year-old black male patient was admitted for acute respiratory distress associated with novel coronavirus disease
2019. (a) The main laboratory results for this patient are shown. He rapidly developed acute kidney injury without hemodynamic compromise.
His respiratory status improved but inflammatory syndrome persisted and renal function further deteriorated. (Continued).
l e t t e r to the ed i to rproteinuria in our patient may have also contributed to
tubular necrosis.
Overall, in contrast to lung injury, kidney injury in
COVID-19 does not appear to include a predominant2inflammatory component. This observation suggests that
collapsing FSGS, potentially resulting from a direct viral effect
on podocytes, probably belongs to the spectrum of COVID-
19–associated renal involvement.Kidney International (2020) -, -–-
Figure 1 | (Continued) (b–d) Illustrative images of his kidney biopsy are shown. Light microscopy study (Masson’s trichrome stain, original
magnification [b,d] 200 and [c] 400) showed the following: first, a severe collapsing glomerulopathy (focal segmental glomerulosclerosis)
characterized by (b,c) the global collapse of shrinking capillary loops and the detachment from the basement membrane of (b) hypertrophic,
proliferating podocytes (or “cobblestone pattern,” [asterisk]), which contained numerous (c) protein reabsorption vacuoles (asterisk). (d) Second,
acute tubular lesions with focal tubular necrosis, dilatation, and the presence of intratubular reabsorption vacuoles (asterisks), reflecting the
heavy proteinuria. Immunofluorescence study did not show any significant immune deposits. (e,f) Electron microscopy study (original
magnification [e] 15,000 and [f] 73,000) disclosed within the podocytes cytoplasm vacuoles containing numerous (e) spherical particles
(asterisk) measuring between 50 to 110 nm and surrounded by (f) spikes measuring 9 to 10 nm (“solar corona” [asterisk]). These particles may
correspond to viral inclusion bodies reported with the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).3 AP50,
alternative pathway activity 50%; Bb, Bb fragment; CCL, CC chemokine ligand; CH50, hemolytic complement activity 50%; CMV, cytomegalovirus;
CXCL, CXC chemokine ligand; CRP, C-reactive protein; G,  109; Hb, hemoglobin; IFN, interferon; IL, interleukin; Lym, lymphocytes; PCR,
polymerase chain reaction; Plt, platelet count; PN, polynuclear neutrophils; SAlb, serum albumin; sC5b-9, soluble C5b-9; SCr, serum creatinine;
TNF-b, tumor necrosis factor-b; UAlb/Cr, urinary albumin over creatinine ratio; UP/Cr, urinary protein over creatinine ratio; WBC, white blood cell
count. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
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